RxDoctor Payments Data

Todd James, DO

Cardiovascular Disease · Grand Jct, CONPI 1467764498

Payments from drug & device makers

What this record shows

19 manufacturers reported payments, led by Abbott at 28.5% of the total. Reporting peaked in 2024 at $3,447 and has fallen 79.0% since, to $724 in 2025.

$10,197in general payments, 2019–2025

Across 203 payments — averaging $50.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Inari Medical, Inc.$2K
  • Medtronic$1K
  • Shockwave Medical, Inc$1K
  • Penumbra, Inc.$892
  • Boston Scientific$676
  • plus $1K from 13 others

What the payments were for

  • Travel & lodging$4,57645%
  • Food & beverage$5,62255%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,197 in reported general payments places this provider in the 85th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$55,546
Medicare patients
127
Services billed
331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$19,647
ClopidogrelClopidogrel Bisulfate72$1,397
Ranolazine ErRanolazine12$851
Atorvastatin Calcium42$696
Metoprolol Succinate31$592
Isosorbide Dinitrate13$567
Isosorbide Mononitrate ErIsosorbide Mononitrate18$323
Rosuvastatin Calcium13$281
Losartan Potassium19$248
Metoprolol Tartrate36$239
Simvastatin14$208
Amlodipine Besylate29$202
Lisinopril23$193
Carvedilol12$173
Furosemide11$83

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Grand Jct

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →